Wells Fargo lowered the firm’s price target on Elevance Health (ELV) to $400 from $478 and keeps an Overweight rating on the shares. The firm is lowering estimates ahead of Q2 print. While Elevance reiterated guidance alongside late May conference appearance, peer commentary suggests some risk to Exchange/Medicaid outlook even before considering MA uncertainty, Wells adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Compelling Valuation and Positive Outlook for Elevance Health Despite Margin Uncertainties
- ELV Upcoming Earnings Report: What to Expect?
- Trump Trade: U.S. slaps 30% tariff rate on EU, Mexico
- Fight brewing over Medicare drug negotiation program, Bloomberg Law reports
- Elevance Health price target lowered to $484 from $555 at UBS